Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q2 2016 · 10-Q
Revenue$68.03M$68.03M+26.3% vs Q2 2015 Net Income$6.90M$6.90MN/M vs Q2 2015 EPS Diluted$0.15$0.15N/M vs Q2 2015 Gross Profit$31,714,000+138.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
Operating Cash Flowderived$9,326,000+272.6% Free Cash Flowderived$3,928,000N/M Margins · derivedGross margin46.6%+21.9 pt vs Q2 2015
Operating margin15.2%+34.2 pt vs Q2 2015
Net margin10.1%+22.5 pt vs Q2 2015
ended Jun 30, 2016 · filed Aug 9, 2016 · 40 d after period end